Learn More
F. Cardoso1*, A. Costa2,3, L. Norton4, E. Senkus5, M. Aapro6, F. André7, C. H. Barrios8, J. Bergh9, L. Biganzoli10, K. L. Blackwell11, M. J. Cardoso12, T. Cufer13, N. El Saghir14, L. Fallowfield15, D. Fenech16, P. Francis17, K. Gelmon18, S. H. Giordano19, J. Gligorov20, A. Goldhirsch21, N. Harbeck22, N. Houssami23, C. Hudis24, B. Kaufman25, I. Krop26, S.(More)
PURPOSE Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)-positive early and advanced breast cancer. In the German Breast Group 26/Breast International Group 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression. METHODS Patients with HER-2-positive breast cancer that progresses(More)
Purpose To assess the benefit from adjuvant systemic tamoxifen therapy in breast cancer risk groups identified by the previously established prognostic 76-gene signature. Methods In 300 lymph node-negative (LNN), estrogen receptor-positive (ER+) breast cancer patients (136 treated with adjuvant tamoxifen, 164 having received no systemic adjuvant therapy),(More)
PURPOSE This phase III randomized open-label clinical trial was designed to evaluate the efficacy and safety of the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen as first-line treatment for metastatic breast cancer (MBC) in postmenopausal women. PATIENTS AND METHODS The study was conducted at 81 centers and enrolled(More)
PURPOSE To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer. PATIENTS AND METHODS Eligible patients were anthracycline-naive and had bidimensionally measurable metastatic breast cancer. Two(More)
515 Background: E is an aromatase inactivator, with demonstrated efficacy in MBC progressing under T, which remained standard 1st line HT over decades. The randomized EORTC phase II trial of E vs T, which showed promising activity in 1st line MBC (Ann. Oncol. 2003, 14: 1391-8) was extended in a phase III reported here, aiming at a true comparison of(More)
BACKGROUND Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by(More)
BACKGROUND Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women. PATIENTS AND METHODS Patients with measurable disease were(More)
The potential value of baseline health-related quality-of-life (HRQOL) and clinical factors in predicting prognosis was examined using data from an international randomised phase III trial which compared doxorubicin and paclitaxel with doxorubicin and cylophosphamide as first line chemotherapy in 275 women with metastatic breast cancer. The European(More)